Clinical data outline the high incidence of pain syndromes in patients with multiple sclerosis, with a significant prevalence of craniofacial manifestations, including trigeminal neuralgia and migraine, which are very difficult to be managed pharmacologically. The common explanation of a localization of demyelinating plaques in areas devoted to pain modulation and integration as a trigger for pain development seems now partially unsatisfactory, since pain is often manifested well before the clinical signs of the pathology and its severity does not correlate with disease progression. This review focuses on additional mechanisms which could be at the basis of pain development in multiple sclerosis, whose identification will help identifying new targets to design more effective analgesic strategies.

What role does multiple sclerosis play in the development of untreatable painful conditions? / S.M. Ceruti. - In: PAIN MANAGEMENT. - ISSN 1758-1869. - 8:1(2018), pp. 37-44. [10.2217/pmt-2017-0038]

What role does multiple sclerosis play in the development of untreatable painful conditions?

S.M. Ceruti
2018

Abstract

Clinical data outline the high incidence of pain syndromes in patients with multiple sclerosis, with a significant prevalence of craniofacial manifestations, including trigeminal neuralgia and migraine, which are very difficult to be managed pharmacologically. The common explanation of a localization of demyelinating plaques in areas devoted to pain modulation and integration as a trigger for pain development seems now partially unsatisfactory, since pain is often manifested well before the clinical signs of the pathology and its severity does not correlate with disease progression. This review focuses on additional mechanisms which could be at the basis of pain development in multiple sclerosis, whose identification will help identifying new targets to design more effective analgesic strategies.
astrocytes; demyelination; fingolimod (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol); microglia; minocycline (7-dimethylamino-6-dimethyl-6-deoxytetracycline); neuropathic pain; satellite glial cells; trigeminal pain
Settore BIO/14 - Farmacologia
2018
28-nov-2017
Article (author)
File in questo prodotto:
File Dimensione Formato  
Ceruti_PAIN_MANAGEMENT_2017.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 506.66 kB
Formato Adobe PDF
506.66 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/532413
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 6
social impact